Sanofi picture

Sanofi sheds dermatology unit for $423 million

pharmafile | December 19, 2011 | News story | Manufacturing and Production, Sales and Marketing |  Canada, Dermik, Sanofi 

Sanofi has completed the sale of its Canadian-based dermatology business Dermik for $422.5 million. 

The unit has been sold to the neurology and dermatology specialist Valeant, which is also based in Canada.

Dermik sales are expected to reach more than $200 million for the year 2011. 

Sanofi has made the decision to divest the unit in order to concentrate on seven key growth areas, including treatments for diabetes and vaccines. 

Advertisement

Dermik has a significant presence in the medical dermatology market in North America, with a strong field force and brands that include acne treatment BenzaClin, Carac for keratoses and facial wrinkle injection Sculptra.

Also included in the deal is Sanofi’s Laval site in Canada, which includes Dermik’s manufacturing facility. Sanofi’s Canadian affiliate, Sanofi Canada, will maintain its operations in greater Montreal.

The company employs around 140 people in its US dermatology division and another 200 at Laval.

The manufacturing facility currently produces approximately 70 formulations and over 200 presentations of tablets, capsules, non-sterile liquids, ointments and creams for third parties – as well as Sanofi.

Ben Adams 

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …

The Gateway to Local Adoption Series

Latest content